Tumor angiogenesis: Molecular facts and therapeutic opportunities;Tumorangiogenese: Molekulare Fakten und therapeutische Möglichkeiten

Chirurg

Volumn 70, Issue 1, 1999, Pages 31-35

  Marme D ^a  

^a TUMOR BIOLOGY CENTER   (Germany)

Author keywords

Anti angiogenic therapy; Oncology; Tumor angiogenesis; VEGF

Indexed keywords

EID: 0345823343     PISSN: 00094722     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001040050600     Document Type: Article

References (20)

1. Barleon B, Siemeister G, Martiny-Baron G, Weindel K, et al (1997) Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells. Cancer Res 57: 5421
2. Boehm T, Folkman J, Browder T, O'Reilly MS (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390: 404
3. Dumont DJ, Gradwohl GJ, Fong GH, Auerbach R, Breitman ML (1993) The endothelial-specific receptor tyrosine kinase tek is a member of a new subfamily of receptors. Oncogene 8: 1293
4. Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18: 4
5. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353
6. Kong HL, Hecht D, Song W, Kovesdi I, et al (1998) Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum Gene Ther 9: 823
7. Kremer C, Breier G, Risau W, Plate KH (1997) Up-regulation of flk-1/vascular endothelial growth factor receptor 2 by its ligand in a cerebral slice culture system. Cancer Res 57: 3852
8. Li J, Brown LF, Hibberd MG, Grossman JD, et al (1996) VEGF, Flk-1 and Flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol 270: 1803
9. Lin P, Buxton JA, Acheson A, Radziejewski C, et al (1998) Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie-2. Proc Natl Acad Sci USA 95: 8829
10. Lin P, Polverini P, Dewhirst M, Shan S, et al (1997) Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie-2 in pathologic vascular growth. J Clin Invest 100: 2072
11. Millauer B, Shawver KL, Plate KH, Risau W, Ullrich A (1994) Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367: 576
12. Pepper MS (1997) Manipulating angiogenesis: from basic science to the bedside. Arterioscler Thromb Vasc Biol 17: 605
13. Rosen LS, Kabbinavar F, Rosen P, Mulay M, et al (1998) Phase I trial of SU5416, a novel angiogenesis inhibitor, in patients with advanced malignancies. Ann Oncol 9: 290
14. Saleh M, Stacker SA, Wilks AF (1996) Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 56: 393
15. Siemeister G, Martiny-Baron G, Marmé D (1998) The pivotal role of VEGF in tumor angiogenesis: Molecular facts and therapeutic opportunities. Cancer Metastasis Rev 17: 241
16. Skobe M, Rockwell P, Goldstein N, Vosseler S, Fusenig NE (1997) Halting angiogenesis suppresses carcinoma cell invasion. Nature Med 3: 1222
17. Suri C, Jones PF, Patan S, Bartunkova PC, et al (1996) Requisite role of angiopoietin-1, a ligand for the Tie2 receptor, during embryonic angiogenesis. Cell 87: 1171
18. Tuder RM, Flook BE, Voelkel NF (1995) Increased gene expression for VEGF and the VEGF receptor KDR/Flk and Flt in lungs exposed to acute or chronic hypoxia. J Clin Invest 95: 1798
19. Warren RA, Yuan H, Matli MR, Gillett NA, Ferrara N (1995) Regulation by vascular endothelial growth factor of human colon cancer tumorigeneses in a mouse model of experimental liver metastasis. J Clin Invest 95: 1789
20. Wood J, Buchdunger E, Cozens R, Hofman F, et al (1997) Pharmacological profile of a potent and orally active inhibitor of VEGF receptor kinases. Proc AACR: a255